RCT | Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer.

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Treatment With Bevacizumab for 30 Months Provides No Benefit Over 15 Months in Ovarian Cancer – Cancer Network

Commentary on Twitter

? LESS IS MORE – Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer
? 15 months remains standard of care ➡️ https://t.co/nKwehjxnHu #gyncsm pic.twitter.com/9DBInZv1t0

— Journal of Clinical Oncology (@JCO_ASCO) December 4, 2022